No-Spa (Drotaverine Hydrochloride)

Drotaverine blocks phosphodiesterase‑4, which raises intracellular cyclic AMP levels. The increased cAMP reduces calcium entry into smooth‑muscle cells, leading to muscle relaxation without significant anticholinergic effects. This mechanism eases spasms in the gastrointestinal, biliary, renal and uterine tissues.

The dosage of No‑Spa is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, age, weight and renal or hepatic function. Healthcare professionals select the appropriate dose and route (intramuscular or intravenous) to achieve optimal therapeutic effect.

Safety data for drotaverine during pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant or nursing should discuss the risks and alternatives with their healthcare provider.

To request No‑Spa, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Compared with anticholinergic agents such as hyoscine, drotaverine provides smooth‑muscle relaxation without significant anticholinergic side effects like dry mouth or blurred vision. Its phosphodiesterase‑inhibiting action offers a distinct mechanism, making it useful when other antispasmodics are contraindicated or poorly tolerated.

No‑Spa should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. Do not freeze the product and keep it in its original packaging until use to maintain stability and potency.

No‑Spa is supplied as an injectable solution for intramuscular or intravenous administration. The healthcare professional selects the appropriate route, prepares the dose under aseptic conditions and administers it slowly to minimize the risk of hypotension or local irritation.

Serious adverse events, although rare, include severe hypotension, allergic reactions such as anaphylaxis, cardiac arrhythmias and blood‑cell abnormalities. Patients should be monitored for signs of these reactions, especially after the first dose or when combined with other hypotensive agents.

No‑Spa is contraindicated in individuals with known hypersensitivity to drotaverine or any of its excipients. Caution is also advised for patients with uncontrolled hypertension, severe cardiac disease, or those taking multiple potent antihypertensive medications, unless a physician determines that benefits outweigh risks.